Zacks Research Issues Positive Outlook for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Analysts at Zacks Research lifted their Q2 2025 earnings per share estimates for BioMarin Pharmaceutical in a report released on Wednesday, January 8th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $0.69 for the quarter, up from their prior estimate of $0.68. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.49 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s Q4 2026 earnings at $0.94 EPS and FY2026 earnings at $3.43 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). The business had revenue of $746.00 million for the quarter, compared to analyst estimates of $703.37 million. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. BioMarin Pharmaceutical’s quarterly revenue was up 28.4% on a year-over-year basis. During the same period last year, the firm posted $0.26 EPS.

BMRN has been the topic of a number of other reports. UBS Group boosted their target price on BioMarin Pharmaceutical from $104.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Wells Fargo & Company lowered their target price on BioMarin Pharmaceutical from $115.00 to $90.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 17th. Stifel Nicolaus reduced their price target on shares of BioMarin Pharmaceutical from $115.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday, September 17th. Wolfe Research started coverage on shares of BioMarin Pharmaceutical in a report on Friday, November 15th. They set an “outperform” rating and a $95.00 price objective on the stock. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $80.00 price objective on shares of BioMarin Pharmaceutical in a report on Wednesday, October 30th. Seven analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $94.20.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $67.38 on Monday. The firm’s fifty day moving average is $65.83 and its 200-day moving average is $74.96. BioMarin Pharmaceutical has a 52 week low of $61.15 and a 52 week high of $96.64. The firm has a market cap of $12.84 billion, a PE ratio of 40.35, a price-to-earnings-growth ratio of 0.65 and a beta of 0.29. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BMRN. Primecap Management Co. CA lifted its stake in shares of BioMarin Pharmaceutical by 0.4% in the third quarter. Primecap Management Co. CA now owns 18,867,435 shares of the biotechnology company’s stock worth $1,326,192,000 after buying an additional 77,350 shares in the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of BioMarin Pharmaceutical by 4.4% during the second quarter. Avoro Capital Advisors LLC now owns 4,557,416 shares of the biotechnology company’s stock valued at $375,212,000 after purchasing an additional 192,416 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of BioMarin Pharmaceutical by 1.9% during the third quarter. Geode Capital Management LLC now owns 3,260,050 shares of the biotechnology company’s stock valued at $228,632,000 after buying an additional 60,692 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in BioMarin Pharmaceutical by 4.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,401,628 shares of the biotechnology company’s stock worth $98,520,000 after buying an additional 55,699 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in BioMarin Pharmaceutical by 38.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,034,457 shares of the biotechnology company’s stock worth $85,178,000 after buying an additional 289,953 shares during the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Charles Greg Guyer sold 5,278 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total transaction of $350,300.86. Following the completion of the transaction, the executive vice president now owns 68,909 shares in the company, valued at $4,573,490.33. This represents a 7.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.85% of the stock is currently owned by insiders.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.